RG: Yeah, it's no longer as hot and sexy because we've all come to realize it's just an RNA binding protein.
LS: I have to admit, when I think about the 3 0 UTR, I think about Newark and LaGuardia and Kennedy, and trying to get all the planes to land.
CM: Where's the UTR in those? RG: It's traffic. She thinks of it as traffic. LS: It's traffic, and I'm thinking about it as being dynamic. Is there an equivalent of the air traffic controller, telling (planes) when to come in?
RG: I guess I would think of it as, there's a whole bunch of it that's not dynamic because they're [the proteins] not being cleared by ribosomes. But then you can see that there'd be the dynamic ones that would come in. It's the second layer I would predict that would be dynamic.
CM: I don't think it's like LaGuardia because you have very abundant RNA binding proteins. I think they already bind, and there is some exchange, but I'm not sure that it's like planes taking off and on.
RG: I like that idea, I think that's kind of a cool thought. You have K D s for a lot of them. We have binding constants for all these things, so in fact, you know, you could make some estimates about on and off rates.
CM RG: In certainly my field, cryo-EM has been transformative. I think many people would argue, . ''there's 5 more years of cryo-EM to solve the all basic structures and then tomography.'' Every cryo-EM person needs to be starting from tomography.
IM: Tomography on 3 0 UTRs is going to be really, really interesting for sure.
RG: You guys probably have more time for this, because we don't know that much.
IM: If the diversity in structures is as great as you're imagining, then you need to be able to look at individual particles instead of averaging.
RG: The one [technique] that I was just thinking about is that, sequencing is here to stay, and the question is how do you process this data? I think talks where they're clustering them, they figure out how to separate them, that's clever. I think the machine learning stuff that you can apply, I think if you're a computational person, you could take these datasets and really mine them in more and more interesting ways. I think that'll have legs.
LS: What I always see as the challenge is, faced with a massive amount of sequencing, how do you know what question to ask of the data?
IM: I think that is the main one, the best question. RG: You dig around for months and find nothing, nothing, nothing, until hopefully you find something.
LS: Well, when you guys do [ribosome] profiling . How do you start?
RG: We always have some hypothesis. We do those obvious things first, but all you get is a stupid scatterplot. Then you've got a few dots up here and you're supposed to come up with something that unifies them, that says, ''these are different, why?'' Then you try every parameter you can think of. (For) the Dhh1 story [a DEAD-box ATPase involved in mRNA decapping and stability], . he tried everything until he read Presnyak's paper (Presnyak et al., Cell 160, 1111 -1124 , and then he's like, ''oh my God, if I sort by codons, boom.'' Our first story, we struggled for half a year looking at those data-nothing, nothing, nothing, until you figure out 3 0 UTRs, where nobody's looking.
CM: I tried to do a lot of reading and basically give them [the bioinformaticians] suggestions. Therefore I always say I'm good at picking because I already have a filter in terms of, ''okay, what could happen? Okay, can this make sense?'' I actually really think you can learn a lot by that. Of course, not everything is published, but sometimes you can use old publications that didn't have the knowledge at the time. Then you integrate your new knowledge with this, and then you think, ''okay, they see already that.'' Then the computational person can really specifically look for that. I basically make these lists. They hate me, but .. RG: It's so different from the data, where you'd get your gel and you'd be like, ''okay, I've pretty much figured this out.'' IM: I love gels. RG: Actually, Harry Noller always said it's like spaghetti. How do you know when to bite it off? You have to publish sometime, right? You've got to have a, ''boom, I'm done, we must be done today,'' because with those types of datasets, you could dig in them forever, and every day you'd come up with something.
LS:
If you know everything, if you cataloged everything that's bound and can bind to a UTR or bound to a protein that's at the UTR and where it is, . that doesn't actually tell you about what it does.
RG: I think you're right. It's never going to be it. You're always going to need multiple pathways. I think the challenge for me with high throughput data as a biochemist-it's the lack of quantitation. It's the correlation plots and GO analysis as the answer. We don't need to get too specific, but I think that's the challenge of these modern approaches. That's the easiest thing to do, and if you don't take it past that, in my view, it's not a story, because you haven't shown . for example, how many proteins are on the messages? All those number things are lost in high throughput. Mass spec is so unquantitative, all these things. You're [to Ian] going to get great candidates for your experiment.
IM: That's why I haven't done it, because I'm like, ''well, I know we're getting a bunch of stuff,'' and then okay, then what do I do?
RG: To me, that's the challenge, is how do you connect. the imprecisions of the high throughput with the control you have in a simple experiment.
LS: I'm going to circle back to something you [Rachel] said at the very beginning, which was you don't have anything clearing out the proteins, and that might change the dynamics. You've published that the ribosome can go into 3 0 UTRs.
RG: I have. That's an example. . I think there are going to be those cases. A ribosome is something that can clear things out, if it's moving ahead.
IM: How often does that happen, though? RG: Well, you know, it was a rare event in this study we published. I would say, another study that was just published, there was a deficiency in the factor Rli1 [a ribosome recycling factor], which is what controls entry there. That's regulated and important, and then you would have a lot of ribosomes reading into the 3 0 UTRs. I think you could have regulated events and we uncovered one in blood cells. I think that's a great example of where you would change occupancy.
LS: It seems like it's regulation to the nth degree, right? Could having the ribosomes go into the UTR be important not for what the ribosome might be doing, but for.. RG: Active restructuring. IM: Restructuring post whatever. RG: I guess the other question is, are there helicases that are recruited in? The ribosome's not the only thing that can clear stuff, and we know DEAD box proteins are .. CM: Because all the RNA binding proteins, they really bind all to helicases. RG: They're everywhere in every process. LS: I think when most people think about 3 0 UTRs, they think about the line everybody draws after the ORF in the onedimensional drawing. CM: You know transcription units can be five kb or 150 kb. The polymerase is the machine. It really just transcribes. How does it know where the last exon (is)? I've thought about this a lot. There are distal marks and RNA binding proteins that cover all this, and there is probably a stop sign in the very end. It makes a few mistakes, but it actually makes so little mistakes compared to how many it could make, and so therefore I think that it (also) has to know.
LS: This idea of context, for microRNAs. Since we've said they're just RNA binding proteins, same deal?
IM: Yeah, well for them, the big issue that the sites have to be accessible. That's sort of obvious. I do kind of wonder about position in three dimensions, if it matters. I think it'd be clear that it's best if you had multiple argonaut binding sites, but whether or not, where the positions are, it's pretty clear that if they're close together in the linear sequence, then that's good and they're cooperative. If you start thinking in the three dimensions, you don't really know, and so things that appear really distal in linear sequence may be closer than you think. . I'm very curious to know that.
